Open an account

Xeris Biopharma Holdings

XERS · NASDAQ

$11.13+$0.18 (+1.64%)TodayMarket closed ·
Prev close $10.95

About XERS

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company is headquartered in Chicago, Illinois and currently employs 435 full-time employees. The company went IPO on 2018-06-21. The company has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. The company also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. The company is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

Employees
435
Headquarters
Chicago, Illinois
Listed
Jun 21, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
xerispharma.com

XERS key statistics

Market cap
1.45B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.35M
Volume
2.90M
Open price
$10.99
High today
$11.35
Low today
$10.96
52 Week high
$11.42
52 Week low
$5.25

Xeris Biopharma Holdings (XERS) at a glance

As of Oct 20, 2026, Xeris Biopharma Holdings (XERS) shares are priced at $11.13, giving the company a market cap of 1.45B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $10.96 and $11.35. The current price is 1.5% above the day's low and 1.9% below its high.

Volume so far is 2.90M shares, in line with the average of 3.35M shares a day.

Over the past year Xeris Biopharma Holdings has ranged from $5.25 to $11.42, and now sits 95% of the way up that range.

Xeris Biopharma Holdings met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.18 per share against an estimate of $0.0034.

The average analyst price target is $12.53, 12.6% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

80%of 5 analyst ratings say Buy
  • Buy80.0%
  • Hold20.0%
  • Sell0.0%
Price target · 9 analystsAvg $12.53
Low
$8.08
Now
$11.13
High
$18.90

XERS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 92.3% on average.

  1. Q3 FY24: reported -$0.11 per share against an estimate of -$0.0918
  2. Q4 FY24: reported -$0.03 per share against an estimate of -$0.0646
  3. Q1 FY25: reported -$0.06 per share against an estimate of -$0.0544
  4. Q2 FY25: reported -$0.01 per share against an estimate of -$0.0281
  5. Q3 FY25: reported $0.00 per share against an estimate of $0.0041
  6. Q4 FY25: reported $0.06 per share against an estimate of $0.0449
  7. Q1 FY26: reported $0.01 per share against an estimate of -$0.0085
  8. Q2 FY26: reported -$0.18 per share against an estimate of $0.0034

XERS news

  • Press releaseBusiness Wire

    Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

  • Press releaseBusiness Wire

    Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  • Lundbeck Is Said To Express Interest In Buying Xeris Biopharma, Bloomberg Reports

  • Press releaseBusiness Wire

    Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

  • Press releaseBusiness Wire

    Xeris Announces Details for XP-8121 Program Overview Webinar

  • Press releaseBusiness Wire

    Xeris Biopharma Reports Second Quarter 2026 Financial Results

  • Press releaseBusiness Wire

    Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

  • Press releaseBusiness Wire

    Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Similar companies

Companies in the same industry as Xeris Biopharma Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.